Pfizer (NYSE:PFE) received a $43.00 price target from equities researchers at Societe Generale in a research note issued on Thursday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Societe Generale’s price objective suggests a potential downside of 0.14% from the stock’s previous close.
A number of other research analysts have also recently issued reports on the stock. Morgan Stanley set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Thursday, September 13th. Barclays reiterated a “neutral” rating and issued a $40.00 target price on shares of Pfizer in a research note on Wednesday, September 26th. BMO Capital Markets reiterated a “buy” rating and issued a $44.00 target price on shares of Pfizer in a research note on Monday, August 27th. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a research report on Wednesday, October 17th. Finally, Goldman Sachs Group restated a “neutral” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Tuesday, August 28th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and nine have assigned a buy rating to the company. Pfizer currently has an average rating of “Hold” and a consensus target price of $43.00.
NYSE:PFE opened at $43.06 on Thursday. Pfizer has a 1 year low of $33.20 and a 1 year high of $45.81. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The company has a market capitalization of $255.32 billion, a PE ratio of 16.25, a PEG ratio of 2.19 and a beta of 0.96.
In other Pfizer news, major shareholder Pfizer Inc bought 55,556 shares of the stock in a transaction on Monday, October 15th. The stock was purchased at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the acquisition, the insider now owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction on Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the sale, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Ballew Advisors Inc acquired a new position in Pfizer in the 1st quarter worth $102,000. Fort L.P. acquired a new position in Pfizer in the 2nd quarter worth $121,000. W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in Pfizer in the 1st quarter worth $132,000. Braun Bostich & Associates Inc. acquired a new position in Pfizer in the 1st quarter worth $139,000. Finally, Smart Portfolios LLC boosted its stake in Pfizer by 43.9% in the 2nd quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 1,200 shares during the period. 69.01% of the stock is owned by hedge funds and other institutional investors.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: What is a Tariff?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.